UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug

Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102. Latest Ratings for URGN Date Firm Action From To Jan 2022 HC Wainwright & Co. Maintains Buy Apr 2021 HC Wainwright & Co. Maintains Buy Apr 2020 Oppenheimer Maintains Outperform View More Analyst Ratings for URGN View the…

Read More